GINGER STEWART: Open Payments
NPI 1275936163 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 108 payments from 19 companies in 2025. Trend: 2023 $1,321 · 2024 $1,959 · 2025 $1,847
Food & beverage: $1,847
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $367 |
| Lilly USA, LLC | 17 | $250 |
| AstraZeneca Pharmaceuticals LP | 10 | $236 |
| Novo Nordisk Inc | 12 | $233 |
| PFIZER INC. | 13 | $159 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $130 |
| Amgen Inc. | 6 | $104 |
| Boston Scientific Corporation | 3 | $66 |
| Phathom Pharmaceuticals, Inc. | 6 | $62 |
| Dexcom, Inc. | 2 | $49 |
Products named: LINZESS, UBRELVY, MOUNJARO, NURTEC ODT, Kerendia, Ozempic, FARXIGA, AIRSUPRA.
Industry payments across MS — which companies pay providers there.
